(soo-NIH-tih-nib MA-layt)
This page contains brief information about sunitinib malate and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Sunitinib malate is approved to treat adults with:
- Gastrointestinal stromal tumor (a type of stomach cancer). It is used in patients whose condition has become worse while taking imatinib mesylate or who are not able to take it.
- Pancreatic cancer. It is used in patients with progressive neuroendocrine tumors that cannot be removed by surgery or has spread.
- Renal cell carcinoma (a type of kidney cancer). It is used:
- In patients with advanced cancer.
- As adjuvant therapy in patients who have had a nephrectomy (surgery to remove the kidney) and have a high risk that the cancer will come back.
Sunitinib malate is also being studied in the treatment of other types of cancer.
More About Sunitinib Malate
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
More About Sunitinib Malate – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Epigenetic Changes Pinpointed as the Cause of Some GISTs
Clinical Trials Accepting Patients
Find Clinical Trials for Sunitinib Malate – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
